http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005102366-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3783c2197eff228c3a368e6a92fcd77e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
filingDate 2005-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d478e002220390e9023340e71005f1eb
publicationDate 2005-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005102366-A3
titleOfInvention Lithium combinations, and uses related thereto
abstract The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
priorityDate 2004-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003027817-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5837701-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003012827-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4264573-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6034091-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5202
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395016
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394200

Total number of triples: 28.